Business Context and Reporting Period
This Form 8-K filing by Cocrystal Pharma, Inc. covers events occurring on February 23, 2015. The report details significant changes to the employment agreements of the Company's Chief Executive Officer and President.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and employment terms rather than financial performance.
Material Changes
- CEO Employment Status: Dr. Gary Wilcox terminated all benefits under his previous employment agreement (dated January 2, 2014), which included a base salary, target bonus, and stock options. He will continue to serve as CEO on an at-will basis.
- President Compensation Reduction: Dr. Sam Lee's employment agreement was amended to eliminate the target bonus and stock option grants previously available. Additionally, severance payable in the event of termination without cause was reduced to six months' salary.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. The primary contingency noted is the change in executive compensation structures, specifically the removal of guaranteed bonuses and equity incentives for top leadership.
Investor Verification Checklist
- Verify the specific terms of the new "at-will" arrangement for CEO Dr. Gary Wilcox.
- Confirm the exact reduction in severance liability for President Dr. Sam Lee.
- Review subsequent filings to determine if these compensation changes impact future equity dilution or cash burn rates.